Chronic Lymphocytic Leukemia

Prevalence in the United States

CLL is the most common adult leukemia in the US



More than 80% will be asymptomatic at the time of diagnosis

Source: American Cancer Society, 2019; National Cancer Institute, SEER, 2019.

Prognostic Subgroups and Associated Genetic Risk Factors in CLL at Diagnosis

Category	Associated Genetic Risk Factors	Therapeutic Strategies
Very high risk	- *del(17p)/TG53* mutation - *BIRC3*	- TP53-independent drugs (eg, rituximab) - Bruton's tyrosine kinase (BTK) inhibitors - Allogeneic hematopoietic stem cell transplantation (HSCT)
High risk	- *del(11q)/ATM* gene - *NOTCH1* gene mutation - *SF3B1* gene mutation	Fludarabine, cyclophosphamide, rituximab (FCR)
Intermediate risk	- Trisomy 12 - Normal karyotype/FISH	Watch and wait
Low risk	Isolated del(13q)	Watch and wait

Source: International Workshop on CLL, 2013.

5-Year Relative Survival Rates

CLL survival rates have improved over time with the introduction of targeted therapies



Source: SEER, National Cancer Institute, 2019.

Approved Targeted Therapies



Source: American Cancer Society, 2019.